News

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43^rd annual J.P. Morgan Healthcare Conference on January 13, 2025.

The live presentation

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.

Bernard Zovighian, chief executive officer, is

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43^rd Annual J.P

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI^® (encorafenib) in combination with cetuximab (marketed as ERBITUX^®) and mFOLFOX6

Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has named Japan Mehta as Chief Information Officer. In this role, Mehta will oversee Humana’s digital and

Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The

Mays Business School at Texas A&M University and leading health and well-being company Humana Inc. (NYSE: HUM) are pleased to announce the winners of the 2024 Humana-Mays Healthcare Analytics Case

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to

Pfizer Inc. (NYSE:PFE) today provided its full-year 2025 guidance⁽¹⁾ and reaffirmed its October 29, 2024 full-year 2024 guidance⁽¹⁾. The accompanying presentation can be found at www.pfizer.com/inv